Trial for J&J schizophrenia drug stopped early due to efficacy

A phase III study for Johnson & Johnson's (JNJ) Paliperidone Palmitate 3-month formulation for schizophrenia has been stopped early due to the drug's effectiveness in delaying relapse when compared with a placebo.

The data is now set to be unblinded.

J&J unit Janssen, which developed the drug, plans to file for FDA approval of the treatment by the end of the year. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs